Zacks: Analysts Expect Bio-Path Holdings, Inc. (BPTH) to Announce -$0.02 Earnings Per Share
Equities analysts forecast that Bio-Path Holdings, Inc. (NASDAQ:BPTH) will announce ($0.02) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Bio-Path Holdings’ earnings. Bio-Path Holdings also reported earnings per share of ($0.02) in the same quarter last year. The business is scheduled to announce its next earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that Bio-Path Holdings will report full-year earnings of ($0.08) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will report earnings of ($0.11) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Bio-Path Holdings.
Bio-Path Holdings (NASDAQ:BPTH) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01).
A number of research firms have commented on BPTH. HC Wainwright set a $5.00 price objective on shares of Bio-Path Holdings and gave the company a “buy” rating in a research note on Friday, August 11th. Zacks Investment Research lowered shares of Bio-Path Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, ValuEngine lowered shares of Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/25/zacks-analysts-expect-bio-path-holdings-inc-bpth-to-announce-0-02-earnings-per-share.html.
Several large investors have recently modified their holdings of the company. HighTower Advisors LLC boosted its holdings in shares of Bio-Path Holdings by 0.3% in the second quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after acquiring an additional 4,000 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after acquiring an additional 5,172 shares in the last quarter. Sabby Management LLC boosted its holdings in shares of Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock valued at $569,000 after acquiring an additional 23,352 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of Bio-Path Holdings in the first quarter valued at about $105,000. Finally, Legal & General Group Plc boosted its holdings in shares of Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after acquiring an additional 1,741,978 shares in the last quarter. 15.16% of the stock is currently owned by institutional investors and hedge funds.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.